156 related articles for article (PubMed ID: 38328494)
1. Treatment Outcomes of Clofazimine-Containing Regimens in Severe
Lee I; Hwang EJ; Kim JY; Yim JJ; Kwak N
Open Forum Infect Dis; 2024 Feb; 11(2):ofad682. PubMed ID: 38328494
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory
Kim BG; Kim H; Kwon OJ; Huh HJ; Lee NY; Baek SY; Sohn I; Jhun BW
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32937940
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex-pulmonary disease in patients unsuitable for standard treatment regimen.
Bao S; Chen S; Zheng J; Ma J; Yang J; Huang H; Duan H
Int J Antimicrob Agents; 2024 Feb; 63(2):107061. PubMed ID: 38103753
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
Zo S; Kim H; Kwon OJ; Jhun BW
Microbiol Spectr; 2022 Aug; 10(4):e0108822. PubMed ID: 35950873
[TBL] [Abstract][Full Text] [Related]
5. A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the
Lee JM; Park J; Choi S; Jhun BW; Kim SY; Jo KW; Hong JJ; Kim LH; Shin SJ
Front Microbiol; 2020; 11():626216. PubMed ID: 33519787
[TBL] [Abstract][Full Text] [Related]
6. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA
Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes and relapse in patients with
Chang CL; Yu CJ; Hsueh PR; Chien JY
Microbiol Spectr; 2023 Sep; 11(5):e0164023. PubMed ID: 37754771
[TBL] [Abstract][Full Text] [Related]
8. Clofazimine serum concentration and safety/efficacy in nontuberculous mycobacterial pulmonary disease treatment.
Watanabe F; Fujiwara K; Furuuchi K; Ito M; Hanada K; Kodama T; Aono A; Mitarai S; Yoshiyama T; Kurashima A; Ohta K; Morimoto K
Respir Med; 2024 Jun; 231():107718. PubMed ID: 38897551
[TBL] [Abstract][Full Text] [Related]
9. Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary Disease.
Kim JY; Park J; Choi Y; Kim TS; Kwak N; Yim JJ
Chest; 2023 Nov; 164(5):1108-1114. PubMed ID: 37423256
[TBL] [Abstract][Full Text] [Related]
10. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Jo KW; Kim S; Lee JY; Lee SD; Kim WS; Kim DS; Shim TS
J Infect Chemother; 2014 Oct; 20(10):602-6. PubMed ID: 24981714
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients.
Cariello PF; Kwak EJ; Abdel-Massih RC; Silveira FP
Transpl Infect Dis; 2015 Feb; 17(1):111-8. PubMed ID: 25620390
[TBL] [Abstract][Full Text] [Related]
13. The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody.
Kawasaki T; Kitada S; Fukushima K; Akiba E; Haduki K; Saito H; Nitta T; Kawano A; Miyazaki A; Nii T; Kuge T; Koba T; Matsuki T; Tsujino K; Miki K; Maekura R; Kida H
Microbiol Spectr; 2022 Feb; 10(1):e0140621. PubMed ID: 34985326
[TBL] [Abstract][Full Text] [Related]
14. Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.
Kwak N; Whang J; Yang JS; Kim TS; Kim SA; Yim JJ
Chest; 2021 Feb; 159(2):517-523. PubMed ID: 32712225
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.
Kim DH; Kim BG; Kim SY; Huh HJ; Lee NY; Koh WJ; Kim H; Kwon OJ; Jhun BW
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640599
[TBL] [Abstract][Full Text] [Related]
16. Role of Clofazimine in Treatment of
Nasiri MJ; Calcagno T; Hosseini SS; Hematian A; Nojookambari NY; Karimi-Yazdi M; Mirsaeidi M
Front Med (Lausanne); 2021; 8():638306. PubMed ID: 33968952
[No Abstract] [Full Text] [Related]
17. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Ogawa K; Sano C
Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Chaisson RE; Keiser P; Pierce M; Fessel WJ; Ruskin J; Lahart C; Benson CA; Meek K; Siepman N; Craft JC
AIDS; 1997 Mar; 11(3):311-7. PubMed ID: 9147422
[TBL] [Abstract][Full Text] [Related]
20. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Martiniano SL; Wagner BD; Levin A; Nick JA; Sagel SD; Daley CL
Chest; 2017 Oct; 152(4):800-809. PubMed ID: 28483608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
